Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Portfolio Pulse from Vandana Singh
Needham initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and a price target of $130, citing the company's diversified CNS portfolio and potential for significant growth. The analyst highlights the commercial success of Auvelity and Sunosi, as well as the promising pipeline assets, including AXS-05, AXS-07, AXS-14, and AXS-12. Needham projects substantial topline growth and significant sales by 2030.
July 22, 2024 | 7:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham initiated coverage on Axsome Therapeutics with a Buy rating and a price target of $130, highlighting the company's diversified CNS portfolio and potential for significant growth. The analyst projects substantial topline growth and significant sales by 2030.
The initiation of coverage with a Buy rating and a high price target by Needham is a strong positive signal for Axsome Therapeutics. The analyst's detailed projections of significant topline growth and promising pipeline assets further support a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100